Hologic, Inc.
Hologic, Inc. (HOLX) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Hologic, Inc. (HOLX), featuring income statements, balance sheets, and cash flow data.
Hologic, Inc. (HOLX) Income Statement & Financial Overview
View the income breakdown for Hologic, Inc. HOLX across both annual and quarterly reports.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $1.005B | $1.02B | $987.90M | $1.01B |
| Cost of Revenue | $623.30M | $446.00M | $430.30M | $443.10M |
| Gross Profit | $382.00M | $575.80M | $557.60M | $568.30M |
| Gross Profit Ratio | $0.38 | $0.56 | $0.56 | $0.56 |
| R&D Expenses | $61.50M | $60.30M | $67.30M | $64.10M |
| SG&A Expenses | $274.10M | $281.80M | $249.20M | $240.30M |
| Operating Expenses | $384.30M | $350.70M | $327.60M | $304.40M |
| Total Costs & Expenses | $1.01B | $792.00M | $757.80M | $747.50M |
| Interest Income | $14.90M | $24.20M | $28.40M | $28.40M |
| Interest Expense | $29.10M | $30.50M | $31.90M | $31.90M |
| Depreciation & Amortization | $48.20M | $74.00M | $74.60M | $72.30M |
| EBITDA | -$7.00M | $352.00M | $328.10M | $344.90M |
| EBITDA Ratio | -$0.007 | $0.34 | $0.33 | $0.34 |
| Operating Income | -$7.00M | $229.80M | $230.10M | $263.90M |
| Operating Income Ratio | -$0.007 | $0.22 | $0.23 | $0.26 |
| Other Income/Expenses (Net) | -$21.50M | $17.70M | -$8.50M | -$23.20M |
| Income Before Tax | -$28.50M | $247.50M | $221.60M | $240.70M |
| Income Before Tax Ratio | -$0.03 | $0.24 | $0.22 | $0.24 |
| Income Tax Expense | -$11.10M | $46.50M | $43.00M | $46.20M |
| Net Income | -$17.40M | $201.00M | $178.60M | $194.50M |
| Net Income Ratio | -$0.02 | $0.20 | $0.18 | $0.19 |
| EPS | -$0.08 | $0.87 | $0.76 | $0.83 |
| Diluted EPS | -$0.08 | $0.87 | $0.76 | $0.82 |
| Weighted Avg Shares Outstanding | $225.77M | $230.28M | $233.77M | $234.60M |
| Weighted Avg Shares Outstanding (Diluted) | $225.77M | $232.11M | $235.97M | $236.47M |
Financial performance has remained strong, with revenue growing from $1.01B in Q3 2024 to $1.005B in Q2 2025. Gross profit continued to perform well, with margins at 38% in the latest quarter. Operating income reached -$7.00M in Q2 2025, holding a steady -1% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$7.00M. Net income dropped to -$17.40M, keeping EPS at -$0.08. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan